Best response to treatment in evaluable patients
| . | Response, n (%)* . | |||
|---|---|---|---|---|
| ≥ PR . | ≥ VGPR . | ≥ nCR . | sCR . | |
| All patients (N = 53) | 52 (98) | 43 (81) | 33 (62) | 22 (42) |
| Treatment duration | ||||
| 4+ cycles (n = 49) | 49 (100) | 43 (88) | 33 (67) | 22 (45) |
| 8+ cycles (n = 36) | 36 (100) | 33 (92) | 28 (78) | 22 (61) |
| 12+ cycles (n = 29) | 29 (100) | 25 (86) | 21 (72) | 18 (62) |
| . | Response, n (%)* . | |||
|---|---|---|---|---|
| ≥ PR . | ≥ VGPR . | ≥ nCR . | sCR . | |
| All patients (N = 53) | 52 (98) | 43 (81) | 33 (62) | 22 (42) |
| Treatment duration | ||||
| 4+ cycles (n = 49) | 49 (100) | 43 (88) | 33 (67) | 22 (45) |
| 8+ cycles (n = 36) | 36 (100) | 33 (92) | 28 (78) | 22 (61) |
| 12+ cycles (n = 29) | 29 (100) | 25 (86) | 21 (72) | 18 (62) |
IMWG indicates International Myeloma Working Group; nCR, near-complete response; PR, partial response; sCR, stringent complete response; and VGPR, very good partial response.
Assessed by Modified IMWG Uniform Criteria with the addition of nCR.